

**Beneficiary Advisory Panel Handout
Uniform Formulary Decisions
17 September 2008**

PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

Table 1: Uniform Formulary Recommendations from the August 2008 DoD P&T Committee Meeting

UF Status / Implementation Period	Generic Name (Brand)
Self-Monitoring Blood Glucose System Test Strips (SMBGS)	
Formulary	Accu-chek Aviva (for Accu-chek Aviva meter)
	Ascensia Contour (for Ascensia Contour meter)
	Freestyle Lite (for Freestyle Lite and Freestyle Freedom Lite meters)
	Precision Xtra (for Precision Xtra meter)
Non-Formulary	One Touch (for One Touch Ultra 2, One Touch Ultra Mini, One Touch Ultra Smart meters)
	TrueTrack (for TrueTrack meter)
	Accu-chek Comfort Curve (for Accu-chek Advantage meter)
	Accu-chek Compact Plus drum (for Accu-check Compact Plus meter)
	Ascensia Breeze 2, Ascensia Elite
	Assure, Assure 3, Assure II, Assure Pro
	Bd Test Strips
	Chemstrip Bg
	Control AST
	Dextrostix Reagent
	Easygluco, Easypro
	Fast Take
	Freestyle test strips (other than Freestyle Lite)
	Glucofilm, Glucolab, Glucometer Dex, Glucometer Elite, Glucose Test Strip, Glucostix
	Optium
	Precision Pcx, Precision Pcx Plus, Precision Q-I-D, Precision Sof-Tact
	Prestige Smart System
	Prodigy
	Quicktek
	Sidekick
	Sof-Tact
	Surestep, Surestep Pro
Test Strip	
Relion Ultima	
Uni-Check	
Plus all other store/private label brand strips not included on Uniform Formulary	
Recommended implementation period	120 days

Figure 1:










Table 2: Self-Monitoring Blood Glucose Systems (SMBGS): Meters meeting minimum technical requirements for DoD

Comparison Parameters	<p>Accu-chek Aviva</p> 	<p>Ascensia Contour</p> 	<p>Freestyle Freedom Lite</p> 	<p>Freestyle Lite</p> 	<p>Precision Xtra</p>  <p>Note: strips are individually foil wrapped</p>
Test Strip	Accu-chek Aviva	Ascensia Contour	Freestyle Lite	Freestyle Lite	Precision Xtra
Manufacturer	Roche	Bayer	Abbott	Abbott	Abbott
Calibration/coding	-Code chip/key inserted into side; pt checks # with strip vial. -Chip left inside until pt removes to check new vial box -New code chip with each box of strips in vial	None (automatic with each strip insertion) -possible 4 codes	None – true no coding; meter and strip are fixed code	None – true no coding; meter and strip are fixed code	-Coding strip inserted; pt checks # with foil strip packet -Pt must remove coding strip and save until box of foil strips is finished -New code strip with each box of strips in vial
Blood sample size	0.6 uL (microliter)	0.6 uL	0.3 uL	0.3 uL	0.6 uL
Alternate site testing	Fingertips, palm, forearm, upper arm, thigh, calf	Fingertips, palm, forearm, abdomen, thigh	Fingertips, hand, forearm, upper arm, thigh, calf	Fingertips, hand, forearm, upper arm, thigh, calf	Fingertips, palm, forearm, upper arm
Test Time	5 sec	5 sec	~5 sec	~5 sec	5 sec
Strip technology	GDH-PQQ	GDH-FAD	GDH-PQQ	GDH-PQQ	GDH-NAD

FAD: flavin adenine dinucleotide; GDH: glucose dehydrogenase; NAD: nicotinamide adenine dinucleotide; PQQ: pyrroloquinolinequinone

Table 2: Self-Monitoring Blood Glucose Systems (SMBGS): Meters meeting minimum technical requirements for DoD (continued)

Comparison Parameters	<p>One Touch Ultra 2</p> 	<p>One Touch Ultra Mini</p> 	<p>One Touch Ultra Smart</p> 	<p>True Track</p> 
Test Strip	One Touch Ultra	One Touch Ultra	One Touch Ultra	TruTrack
Manufacturer	Lifescan (Johnson & Johnson)	Lifescan (Johnson & Johnson)	Lifescan (Johnson & Johnson)	Home Diagnostics
Calibration/coding	Manual; pt checks code on vial when strip inserted into machine; must use buttons to confirm code	Manual; pt checks code on vial when strip inserted into machine; must use buttons to confirm code	Manual; pt checks code on vial when strip inserted into machine; must use buttons to confirm code	Code chip inserted into meter; pt matches code chip in meter with that on vial
Blood sample size	1 uL (microliter)	1 uL	1 uL	1 uL
Alternate site testing	Fingertips, palm, forearm	Fingertips, palm, forearm	Fingertips, palm, forearm	Fingertip and forearm
Test Time	5 sec	5 sec	5 sec	10 sec
Strip technology	Glucose oxidase	Glucose oxidase	Glucose oxidase	Glucose oxidase

FAD: flavin adenine dinucleotide; GDH: Glucose dehydrogenase; NAD: nicotinamide adenine dinucleotide; PQQ: pyrroloquinolinequinone


**Table 3: Uniform Formulary Recommendations from the August 2008
DoD P&T Committee Meeting**

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Overactive Bladder Drugs			
Formulary	Darifenacin (Enablex)	tabs	No
	Oxybutynin IR (Ditropan)	tabs, syrup	Yes
	Oxybutynin ER (Ditropan XL)	tabs	Yes
	Oxybutynin transdermal (Oxytrol)	patch	No
	Solifenacin (Vesicare)	tabs	No
	Tolterodine ER (Detrol LA)	caps	No
	Trospium ER (Sanctura XR)	caps	No
Non-Formulary	Tolterodine IR (Detrol)	tabs	No
	Sanctura IR (Trospium IR)	tabs	No
Recommended implementation period	90 days		

ER: extended release
IR: immediate release

Figure 2:

OAB Utilization – All POS July 06 – June 08



Source: PDTS


Table 4: Desvenlafaxine (Pristiq): Uniform Formulary Recommendations from for the Anti-depressant 1 (AD-1) Drugs

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?	
Antidepressant 1 (AD-1s)				
Formulary	Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)			
	Venlafaxine IR (Effexor)	tabs	Yes	
	Venlafaxine ER (Effexor XR)	caps	No	
	Selective Reuptake Inhibitors (SSRI)			
	Fluoxetine (excludes Prozac Weekly, Sarafem)	caps, syrup	Yes	
	Citalopram	tabs	Yes	
	Paroxetine HCl IR	tabs	Yes	
	Paroxetine mesylate (Pexeva)	tabs	No	
	Sertraline (Zoloft)	tabs	Yes	
	Fluvoxamine (Luvox brand discontinued)	tabs	Yes	
	Serotonin-Antagonist/Reuptake Inhibitors (SARIs)			
	Nefazodone	tabs	Yes	
	Trazodone	tabs	Yes	
	Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs)			
	Bupropion immediate release (Wellbutrin)	tabs	Yes	
	Bupropion sustained release (Wellbutrin SR)	tabs	Yes	
	Alpa-2 Receptor Antagonists			
	Mirtazapine (Remeron)	Tabs,	Yes	
	Non-Formulary	Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)		
		Desvenlafaxine (Pristiq) - recommended for NF August 2008	tab	No
Duloxetine (Cymbalta)		caps	No	
Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs)				
Bupropion ER (Wellbutrin XL)		tabs		
Selective Reuptake Inhibitors (SSRI)				
Fluoxetine weekly (Prozac Weekly)		caps	No	
Fluoxetine in special packaging for premenstrual dysphoric disorder (Sarafem)		caps, tabs	Yes	
Escitalopram (Lexapro)		tabs	No	
Paroxetine ER (Paxil CR)		Tabs	Nt	
Recommended implementation period	60 days for Pristiq			

ER: extended release
 IR: immediate release
 SR: sustained release

Figure 3:

AD-1 Utilization - All POS July 06 – June 08



Source: PDTS


Table 5: Nisoldipine Geomatrix (Sular Geomatrix): Uniform Formulary Recommendations for the Calcium Channel Blockers (CCBs)

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Calcium Channel Blockers (CCBs)			
Formulary	Dihydropyridine (DHP) CCBs		
	Amlodipine (Norvasc)	tabs	Yes
	Nisoldipine coat core (Sular)	tabs	Yes
	Felodipine (Plendil)	tabs	Yes
	Nifedipine IR (not used for hypertension)	caps	Yes
	Nifedipine ER (various products Adalat CC / Procardia XL/CR)	tabs, caps	Yes
	Nimodipine (Nimotop) – not approved for hypertension	caps	Yes
	Diltiazem products		
	Diltiazem SR (various products)	tabs, caps	Yes
	Diltiazem ER (various products)	tabs, caps	Yes
	Verapamil CCBs		
	Verapamil IR	tabs, caps	Yes
	Verapamil SR (various products)	tabs, caps	Yes
Non-Formulary	Dihydropyridine (DHP) CCBs		
	Nisoldipine Geomatrix (Sular Geomatrix) – recommended for NF August 2008	Tabs	No
	Isradipine IR (DynaCirc)	caps	No
	Isradipine SR (DynaCirc CR)	caps	No
	Nicardipine IR (Cardene)	caps	Yes
	Nicardipine SR (Cardene SR)	caps	No
	Diltiazem CCB products		
	Diltiazem ER for HS dosing (Cardizem LA)	tabs	No
	Verapamil CCB products		
	Verapamil ER (Verelan)	tabs	No
	Verapamil ER for HS dosing (Verelan PM)	tabs	No
Verapamil ERfor HS dosing (Covera HS)	tabs	No	
Recommended implementation period	60 days for Sular Geomatrix		

ER: extended release
 HS: bedtime
 IR: immediate release
 SR: sustained release

Figure 4:

CCB Utilization – All POS July 06 - June 08



Source: PDTS

Table 6: Uniform Formulary Implementation Plan Summary

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Aug 08	Self-Monitoring Blood Glucose System Test Strips	<ul style="list-style-type: none"> ▪ One Touch (for One Touch Ultra 2, Ultra Mini, and Ultra Smart meters) ▪ TrueTrack strips (for TrueTrack meter) ▪ Accu-chek Comfort Curve strips (for Accu-chek Advantage meter) ▪ Accu-chek Compact Plus drum (for Accu-check Compact Plus meter) ▪ Accu-chek Simplicity, Ascensia Autodisk, Ascensia Breeze 2, Ascensia Elite, Assure, Assure 3, Assure II, Assure Pro, Bd Test Strips, Chemstrip Bg, Control AST, Dextrostix Reagent, Easygluco, Easypro, Fast Take, Freestyle test strips (other than Freestyle Lite), Glucofilm, Glucolab, Glucometer Dex, Glucometer Elite, Glucose Test Strip, Glucostix, Optium, Precision Pcx, Precision Pcx Plus, Precision Q-I-D, Precision Sof-Tact, Prestige Smart System, Prodigy, Quicktek, Sidekick, Sof-Tact, Surestep, Surestep Pro, Test Strip, Relion Ultima, Uni-Check ▪ Plus all other store/private label brand strips not included on Uniform Formulary (see the BCF/ECF column) 	58,142	12,271	33,658	12,231	120	Allow time for patients to receive new meters	No
Aug 08	Overactive Bladder Drugs	<ul style="list-style-type: none"> ▪ Tolterodine IR (Detrol) ▪ Trospium IR (Sanctura) 	4,215	235	1,210	2,770	90	Typical 90-day implementation period	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Aug 08	Antidepressant – 1s	<ul style="list-style-type: none"> Desvenlafaxine (Pristiq) 	745	0	694	51	60	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Nov 05</i> <ul style="list-style-type: none"> paroxetine HCl CR (Paxil) fluoxetine 90 mg for weekly administration (Prozac Weekly) fluoxetine in special packaging for PMDD (Sarafem) escitalopram (Lexapro) duloxetine (Cymbalta) bupropion extended release (Wellbutrin XL) 	See previous meetings below in table			See previous meetings below in table	See previous meetings below in table	No	
Aug 08	Calcium Channel Blockers	<ul style="list-style-type: none"> Nisoldipine geomatrix (Sular geomatrix) 	2,027	56	1,188	783	60	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Aug 05</i> <ul style="list-style-type: none"> amlodipine (Norvasc) <ul style="list-style-type: none"> Nov 07: removed from NF status isradipine IR (Dynacirc) isradipine ER (Dynacirc CR) nicardipine IR (Cardene, generics) nicardipine SR (Cardene SR) verapamil ER (Verelan) verapamil ER for bedtime dosing (Verelan PM, Covera HS) diltiazem ER for bedtime dosing (Cardizem LA) 	See previous meetings below in table			See previous meetings below in table	See previous meetings below in table	No	

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Jun 08	Triptans	<ul style="list-style-type: none"> Almotriptan (Axert) Frovatriptan (Frova) Naratriptan (Amerge) 	3,763	208	3,212	343	(26 Nov 2008) 90 days	Typical 90-day implementation period	No
Jun 08	Osteoporosis Agents	<ul style="list-style-type: none"> Salmon-calcitonin (Miacalcin) 	2,914	945	1,948	1,021	(26 Nov 2008) 90 days	Typical 90-day implementation period	No
Jun 08	Newer Antihistamines (NAs) (new drug in previously reviewed class); Original decision Aug 07	<ul style="list-style-type: none"> Levocetirizine (Xyzal) 	19,254	0	19,254	0	(29 Oct 2008) 60 days	New drug in already reviewed class	No
		<i>Original Meeting Aug 07</i> <ul style="list-style-type: none"> desloratadine (Clarinet) desloratadine/pseudoephed. (Clarinet D) 	27,396	60	20,102	7,234	See previous meetings below in table	Typical 90-day implementation period	No
Jun 08	Leukotriene Modifiers (LMs) (new drug in previously reviewed class); Original decision Aug 07	<ul style="list-style-type: none"> Zileuton extended release (Zyflo CR) 	288	0	288	0	(29 Oct 2008) 60 days	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Aug 07</i> <ul style="list-style-type: none"> zileuton (Zyflo) 	144	4	110	31	See previous meetings below in table	Typical 90-day implementation period	No
Jun 08	Beta Adrenergic Receptor Blockers (ABAs) (new drug in previously reviewed class); Original decision Nov 07	<ul style="list-style-type: none"> Nebivolol (Bystolic) 	2,462	0	2,462	0	(29 Oct 2008) 60 days	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Nov 07</i> (No drugs designated non formulary)	0	0	0	0	See previous meetings below in table	No meds moved to non-formulary status	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Jun 08	Renin Antihypertensive Agents (RAAs) (new drug in previously reviewed class);	ARB/CCB combos (Jun 08) ▪ Olmesartan / amlodipine (Azor)	2,641	0	2,641	0	(29 Oct 2008) 60 days	New drug in already reviewed class with current low utilization	No
		ARB/CCB combos (Nov 07) ▪ valsartan / amlodipine (Exforge)	2,376	0	2,376	0	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
		ARBs – (May 07 meeting) ▪ eprosartan (Teveten) ▪ eprosartan HCTZ (Teveten HCT) ▪ irbesartan (Avapro) ▪ irbesartan HCTZ (Avalide) ▪ olmesartan (Benicar) ▪ olmesartan HCTZ (Benicar HCT) ▪ valsartan (Diovan) ▪ valsartan HCTZ (Diovan HCT) ACE/CCB combos – Feb 06 meeting ▪ felodipine/enalapril (Lexxel) ▪ verapamil/trandolapril (Tarka) ACE Inhibitors (Aug 05 meeting) ▪ moexipril (Univasc), ▪ moexipril / HCTZ (Uniretic) ▪ perindopril (Aceon) ▪ quinapril (Accupril) ▪ quinapril / HCTZ (Accuretic) ▪ ramipril (Altace)	See previous meetings for affected beneficiaries for each subclass				See previous meetings below in table	See previous meetings below in table	
Nov 07	Benign Prostatic Hypertension (BPH) Alpha Blockers (ABs)	▪ tamsulosin (Flomax)	64,783	1,426	40,161	23,196	(16 Apr 2008) 60-days	3 rd class for Step Therapy	Yes
Nov 07	Targeted Immunomodulatory Biologics (TIBs)	▪ etanercept (Enbrel) ▪ anakinra (Kineret)	7,397	1,939	4,149	1,309	(18 Jun 2008) 90-days	Typical 90-day implementation period	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Nov 07	Attention Deficit Hyperactivity Disorder (ADHD) / Narcolepsy agents (new drug in previously reviewed class); Previous decision Nov 06	<ul style="list-style-type: none"> lisdexamfetamine (Vyvanse) 	2,200 Rxs	0	2,200 Rxs	0	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
		<i>Original decision Nov 06</i> <ul style="list-style-type: none"> Dexmethylphenidate IR (Focalin) Dexmethylphenidate SODAS (Focalin XR) Methylphenidate transdermal patch (Daytrana) 	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	
Nov 07	Contraceptive Agents (new drug in previously reviewed class); Previous decisions May 06, Nov 06	<ul style="list-style-type: none"> EE 20 mcg / levonorgestrel 0.09 mg (Lybrel) 	290 Rxs	2 Rxs	263 Rxs	25 Rxs	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
		<i>Previous meetings May 06 & Nov 06</i> <ul style="list-style-type: none"> EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale) EE 25 mcg / norethindrone 0.4 mg (Ovcon 35) EE 50 mcg / norethindrone 1 mg (Ovcon 50) EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe) EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe) EE 30/10 mcg/ 0.15 mg levonorgestrel for 	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Seasonale, packaged as a 3-month supply; Loestrin 24 FE and Seasonique to coincide with Seasonale decision	
		<ul style="list-style-type: none"> Seasonique: 161 (from Apr 06-Oct 06) 	0 Rxs	112 Rxs	4 Rxs				

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		extended use (Seasonique)	Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs			
Aug 07	Nasal Corticosteroid Agents (new drug in previously reviewed class); Original decision Nov 05	<ul style="list-style-type: none"> fluticasone furoate (Veramyst) 	650	0	650	0	TMOP & TRRx: 60-days for current users; \$22 co-pay in effect immediately for new users MTF: No later than 60 days	New drug in already reviewed class with current low utilization	No
		<i>Original Decision: Nov 05</i> <ul style="list-style-type: none"> beclomethasone dipropionate (Beconase AQ, Vancenase AQ) budesonide (Rhinocort Aqua) triamcinolone (Nasacort AQ) 					19 Jan 06 (90 days)	Substantial number of beneficiaries	
Aug 07	Growth Stimulating Agents (GSAs)	<ul style="list-style-type: none"> somatropin (Genotropin, Genotropin Miniquick) somatropin (Humatrope) somatropin (Omnitrope) somatropin (Saizen) 	653	77	310	266	TMOP & TRRx: 60-days for current users; MTF: No later than 60 days	Low number of affected beneficiaries affected	No
May 07	Antilipidemic II Agents (LIP-2s)	<ul style="list-style-type: none"> fenofibrate nanocrystallized (Tricor) fenofibrate micronized (Antara) omega-3 fatty acids (Omacor) colesevelam (Welchol) 	83,612	18,849	44,402	20,361	24 Oct 07 (90 days)	Typical 90-day implementation period	No
May 07	5-Alpha Reductase Inhibitors (5-ARIs)	<ul style="list-style-type: none"> dutasteride (Avodart) 	20,917	1,087	12,830	7,000	24 Oct 07 (90 days)	Typical 90-day implementation period	No
May 07 (Update from Feb 05)	PPIs	<ul style="list-style-type: none"> lansoprazole (Prevacid) omeprazole/sodium bicarbonate (Zegerid) pantoprazole (Protonix) rabeprazole (Aciphex) 	453,525	212,130	178,120	63,275	24 Oct 07 (90 days)	Typical 90-day implementation period	Yes

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 07 (Update from Feb 05)	ARBs	<ul style="list-style-type: none"> ▪ eprosartan (Teveten) ▪ eprosartan HCTZ (Teveten HCT) ▪ irbesartan (Avapro) ▪ irbesartan HCTZ (Avalide) ▪ olmesartan (Benicar) ▪ olmesartan HCTZ (Benicar HCT) ▪ valsartan (Diovan) ▪ valsartan HCTZ (Diovan HCT) 	228,581	68,059	109,595	50,930	21 Nov 07 (120 days)	Reservations regarding ESI ability to handle implementation	No
Feb 07	Newer Sedative Hypnotics	<ul style="list-style-type: none"> ▪ Ramelteon (Rozerem) ▪ Zaleplon (Sonata) ▪ Zolpidem ER (Ambien CR) 	40,447	5,878	31,550	3,019	1 Aug 07 (90 days)	First time automated PA with step edit	Yes
Feb 07	Narcotic Analgesics	<ul style="list-style-type: none"> ▪ Tramadol ER (Ultram ER) 	1,088	0	46	1,042	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Feb 07	Glaucoma Agents	<ul style="list-style-type: none"> ▪ Travoprost (Travatan, Travatan Z) ▪ Timolol maleate (Istalol) ▪ Timolol hemihydrate (Betimol) ▪ Brinzolamide (Azopt) 	17,139	1,735	12,267	3,117	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Feb 07	MAOI Antidepressants	<ul style="list-style-type: none"> ▪ Selegiline transdermal system (Emsam) 	168	0	157	11	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Nov 06	ADHD	<ul style="list-style-type: none"> ▪ Dexmethylphenidate IR (Focalin) ▪ Dexmethylphenidate SODAS (Focalin XR) ▪ Methylphenidate transdermal patch (Daytrana) 	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	No
Nov 06	Older Sedative Hypnotics	-	0	0	0	0	18 Apr 07 (90 days)	No medications moved to non-formulary status	No
Aug 06	TZDs	-	0	0	0	0	Not applicable	No medications moved to non-formulary status	No
Aug 06	H2 Antagonists / GI protectants	-	0	0	0	0	Not applicable	No medications moved to non-formulary status	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Aug 06	Antilipidemic I Agents	<ul style="list-style-type: none"> Rosuvastatin (Crestor) Atorvastatin / amlodipine (Caduet) 	44,078	851	36,133	6,921	1 Feb 07 (90 days)	Small number of beneficiaries affected	No
May 06	Antiemetics	<ul style="list-style-type: none"> Dolasetron (Anzemet) 	852	14	668	170	27 Sept 06 (60 days)	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)	No
May 06 update for new drugs Nov 06	Contraceptive Agents	<i>Original Decision May 06</i> <ul style="list-style-type: none"> EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale) EE 25 mcg / norethindrone 0.4 mg (Ovcon 35) EE 50 mcg / norethindrone 1 mg (Ovcon 50) EE 20/30/35 mcg / norethindrone 1 mg (Elostep Fe) 	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Relatively low number of beneficiaries affected, but a high proportion are receiving Seasonale, which is packaged as a 3-month supply	No
		<i>Nov 06</i> <ul style="list-style-type: none"> EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe) EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique) 	Seasonique 161 (from Apr 06-Oct 06)	0 Rxs	112 Rxs	4 Rxs	Jan 24 07 (60 days; to coincide with Seasonal)	Small number of beneficiaries affected	No
			Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs			
Feb 06	OABs	<ul style="list-style-type: none"> tolterodine IR (Detrol) oxybutynin patch (Oxytrol) tropium (Sanctura) 	19,118	2,596	13,471	3,051	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Feb 06	Misc Anti-hypertensive Agents	<ul style="list-style-type: none"> ▪ felodipine/enalapril (Lexxel) ▪ verapamil/trandolapril (Tarka) 	5,946	336	4,472	1,138	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted	No
Feb 06	GABA-analogs	<ul style="list-style-type: none"> ▪ pregabalin (Lyrica) 	30,649	1,120	27,566	1,963	28 Jun 06 (60 days)	Small number of beneficiaries affected	No
Nov 05	Alzheimer's Drugs	<ul style="list-style-type: none"> ▪ tacrine (Cognex) 	5	0	3	2	19 Apr 06 (90 days)	Small number of beneficiaries affected	No
Nov 05	Nasal Corticosteroid Agents	<ul style="list-style-type: none"> ▪ beclomethasone dipropionate (Beconase AQ, Vancenase AQ) ▪ budesonide (Rhinocort Aqua) ▪ triamcinolone (Nasacort AQ) 	96,999	13,556	73,381	10,062	19 Apr 06 (90 days)	Substantial number of beneficiaries affected	No
Nov 05	Macrolide/Ketolide Antibiotics	<ul style="list-style-type: none"> ▪ azithromycin 2 gm (Zmax) ▪ telithromycin (Ketek) 	Total number not provided; antibiotics are used to treat acute infections				22 Mar 06 (60 days)	Small number of beneficiaries affected, Medication used to treat acute (not chronic) infections not likely to require therapy change	No
Nov 05	Antidepressants I	<ul style="list-style-type: none"> ▪ paroxetine HCl CR (Paxil) ▪ fluoxetine 90 mg for weekly administration (Prozac Weekly) ▪ fluoxetine in special packaging for PMDD (Sarafem) ▪ escitalopram (Lexapro) ▪ duloxetine (Cymbalta) ▪ bupropion extended release (Wellbutrin XL) 	182,916	52,624	118,582	11,710	19 Jul 06 (180 days)	Substantial number of beneficiaries affected	No
Aug 05	Alpha Blockers for BPH	<ul style="list-style-type: none"> ▪ tamsulosin (Flomax) 	89,926	26,692	47,674	15,560	15 Feb 06 (120 days)	Substantial number of beneficiaries affected	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Aug 05	CCBs	<ul style="list-style-type: none"> ▪ amlodipine (Norvasc) <ul style="list-style-type: none"> ○ Nov 07: amlodipine removed from NF status ▪ isradipine IR (Dynacirc) ▪ isradipine ER (Dynacirc CR) ▪ nicardipine IR (Cardene, generics) ▪ nicardipine SR (Cardene SR) ▪ verapamil ER (Verelan) ▪ verapamil ER for bedtime dosing (Verelan PM, Covera HS) ▪ diltiazem ER for bedtime dosing (Cardizem LA) 	274,616	133,794	101,345	39,477	15 Mar 06 (150 days)	Substantial number of beneficiaries affected	No
Aug 05	ACE Inhibitors & ACE Inhibitor / HCTZ Combinations	<ul style="list-style-type: none"> ▪ moexipril (Univasc), ▪ moexipril / HCTZ (Uniretic) ▪ perindopril (Aceon) ▪ quinapril (Accupril) ▪ quinapril / HCTZ (Accuretic) ▪ ramipril (Altace) 	158,101	77,159	57,982	22,959	16 Feb 06 (120 days)	Substantial number of beneficiaries affected	No
May 05	PDE-5 Inhibitors	<ul style="list-style-type: none"> ▪ sildenafil (Viagra) ▪ tadalafil (Cialis) 	128,007	55,161	49,850	22,996	12 Oct 05 (90 days)	Substantial number of beneficiaries affected	No
May 05 updated for new drug Nov 06	Topical Antifungals*	<ul style="list-style-type: none"> ▪ econazole ▪ ciclopirox ▪ oxiconazole (Oxistat) ▪ sertaconazole (Ertaczo) ▪ sulconazole (Exelderm) 	49,743	14,266	33,430	2,047	17 Aug 05 (30 days)	Medication used to treat acute (not chronic) infections not likely to require therapy change	No
		<ul style="list-style-type: none"> ▪ miconazole 0.25%, zinc oxide 15%, white petrolatum 82.35% (Vusion) 	581 (Apr 06-Oct 06) (UU not applicable)	7	571	3	21 Feb 07 (60 days)	Small numbers of beneficiaries affected	No
May 05	MS-DMDs	-	0	0	0	0	Not applicable	No medications moved to non-formulary status	No
Feb 05	ARBs	<ul style="list-style-type: none"> ▪ eprosartan (Teveten) ▪ eprosartan/HCTZ (Teveten HCT) 	2,184	13	1,644	527	17 Jul 05 (90 days)	Recommended 30-day implementation overturned; 90-day BAP recommendation accepted	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Feb 05	PPIs	<ul style="list-style-type: none"> esomeprazole (Nexium) 	138,739	6,691	117,520	14,528	17 Jul 05 (90 days)	Substantial number of beneficiaries affected	

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary

CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release

5-ARI = 5-Alpha Reductase Inhibitors; ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GSAs = Growth Stimulating Agents; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; Leukotriene Modifiers = LMs; LIP-1s = Antilipidemic I; LIP-2s = Antilipidemic II; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; NAs = Newer Antihistamines; OABs = Overactive Bladder Medications;

PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; RAAs = Renin Antihypertensive Agents; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])